Considering the benefits of active immunotherapy and studies suggesting the antitumoral advantages of a polyclonal response over monoclonal antibodies (25–27), developing a vaccine against HER3 could be a strategy for treating cancers in which the activation of this receptor plays a fundamental role. The gene discussed is ERBB3; the disease is cancer.